Switch theme
Sign up to access all valuation multiples
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
2013
430
LTM Revenue $273M
LTM EBITDA -$168M
-$420M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Arvinas has a last 12-month revenue (LTM) of $273M and a last 12-month EBITDA of -$168M.
In the most recent fiscal year, Arvinas achieved revenue of $263M and an EBITDA of -$244M.
Arvinas expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arvinas valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $273M | XXX | $263M | XXX | XXX | XXX |
| Gross Profit | $273M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$168M | XXX | -$244M | XXX | XXX | XXX |
| EBITDA Margin | -62% | XXX | -92% | XXX | XXX | XXX |
| EBIT | -$204M | XXX | -$250M | XXX | XXX | XXX |
| EBIT Margin | -75% | XXX | -95% | XXX | XXX | XXX |
| Net Profit | -$158M | XXX | -$199M | XXX | XXX | XXX |
| Net Margin | -58% | XXX | -76% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Arvinas's stock price is $7.
Arvinas has current market cap of $524M, and EV of -$420M.
See Arvinas trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$420M | $524M | XXX | XXX | XXX | XXX | $-2.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Arvinas has market cap of $524M and EV of -$420M.
Arvinas's trades at -1.6x EV/Revenue multiple, and 1.7x EV/EBITDA.
Equity research analysts estimate Arvinas's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arvinas has a P/E ratio of -3.3x.
See valuation multiples for Arvinas and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $524M | XXX | $524M | XXX | XXX | XXX |
| EV (current) | -$420M | XXX | -$420M | XXX | XXX | XXX |
| EV/Revenue | -1.5x | XXX | -1.6x | XXX | XXX | XXX |
| EV/EBITDA | 2.5x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBIT | 2.1x | XXX | 1.7x | XXX | XXX | XXX |
| EV/Gross Profit | -1.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.3x | XXX | -2.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArvinas's last 12 month revenue growth is -15%
Arvinas's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $1.2M for the same period.
Arvinas's rule of 40 is -518% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arvinas's rule of X is -98% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Arvinas and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -15% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -62% | XXX | -92% | XXX | XXX | XXX |
| EBITDA Growth | -34% | XXX | -52% | XXX | XXX | XXX |
| Rule of 40 | -518% | XXX | -107% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -98% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 132% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 195% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arvinas acquired XXX companies to date.
Last acquisition by Arvinas was XXXXXXXX, XXXXX XXXXX XXXXXX . Arvinas acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Arvinas founded? | Arvinas was founded in 2013. |
| Where is Arvinas headquartered? | Arvinas is headquartered in United States of America. |
| How many employees does Arvinas have? | As of today, Arvinas has 430 employees. |
| Who is the CEO of Arvinas? | Arvinas's CEO is Dr. John G. Houston, PhD. |
| Is Arvinas publicy listed? | Yes, Arvinas is a public company listed on NAS. |
| What is the stock symbol of Arvinas? | Arvinas trades under ARVN ticker. |
| When did Arvinas go public? | Arvinas went public in 2018. |
| Who are competitors of Arvinas? | Similar companies to Arvinas include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Arvinas? | Arvinas's current market cap is $524M |
| What is the current revenue of Arvinas? | Arvinas's last 12 months revenue is $273M. |
| What is the current revenue growth of Arvinas? | Arvinas revenue growth (NTM/LTM) is -15%. |
| What is the current EV/Revenue multiple of Arvinas? | Current revenue multiple of Arvinas is -1.5x. |
| Is Arvinas profitable? | Yes, Arvinas is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Arvinas? | Arvinas's last 12 months EBITDA is -$168M. |
| What is Arvinas's EBITDA margin? | Arvinas's last 12 months EBITDA margin is -62%. |
| What is the current EV/EBITDA multiple of Arvinas? | Current EBITDA multiple of Arvinas is 2.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
